Abstract
Diabetes Technology & TherapeuticsVol. 14, No. 11 EditorialsBiosimilar Insulins: How Will This Story Evolve?Lutz HeinemannLutz HeinemannSearch for more papers by this authorPublished Online:26 Oct 2012https://doi.org/10.1089/dia.2012.0247AboutSectionsView articleView Full TextPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byCross-sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program24 April 2018 | Journal of Diabetes Investigation, Vol. 9, No. 6The Disappointment of the Biosimilar1 January 2021 | Journal of Law, Medicine & Ethics, Vol. 46, No. 3Controlled release of biologics for the treatment of type 2 diabetesJournal of Controlled Release, Vol. 240Why Is There No Generic Insulin? Historical Origins of a Modern ProblemNew England Journal of Medicine, Vol. 372, No. 12 Volume 14Issue 11Nov 2012 InformationCopyright 2012, Mary Ann Liebert, Inc.To cite this article:Lutz Heinemann.Biosimilar Insulins: How Will This Story Evolve?.Diabetes Technology & Therapeutics.Nov 2012.986-988.http://doi.org/10.1089/dia.2012.0247Published in Volume: 14 Issue 11: October 26, 2012PDF download
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
